Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib
Open Access
- 31 August 2004
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 91 (S2) , S11-S17
- https://doi.org/10.1038/sj.bjc.6602062
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- O-240 Clinical experience with gefitinib (‘Iressa’, ZD1839): an overview of safety and tolerabilityLung Cancer, 2003
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupJournal of Clinical Oncology, 2003
- P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2)Lung Cancer, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Lung and Head and neck cancers (Abstract No. 467-492)Annals of Oncology, 2002
- Blockade of Epidermal Growth Factor Receptor Signaling on Tumor Cells and Tumor-Associated Endothelial Cells for Therapy of Human CarcinomasThe American Journal of Pathology, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Survey on the treatment of non-small cell lung cancer (NSCLC) in England and WalesEuropean Respiratory Journal, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995